Buy Us a Cup of Coffee

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

MALVERN, PA — Aclaris TherapeuticsAclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved topical treatment for raised seborrheic keratoses (SKs) – benign skin growths that may be a cosmetic concern, especially when they appear on the face, neck or chest area.

“With ESKATA, dermatologists may now offer their patients a topical treatment option for raised SKs,” said Brett Fair, Chief Commercial Officer of Aclaris. “Our mission at Aclaris is to identify, develop and commercialize innovative therapies to address unmet needs in aesthetics and medical dermatology and immunology. The introduction of ESKATA – six years in the making – delivers on this goal.”

ESKATA is a proprietary, high-concentration stabilized hydrogen peroxide topical solution designed for in-office application by a healthcare provider. It is a targeted treatment applied directly to the raised SK using a pen-like applicator. Typically, two treatments are required and scheduled approximately three weeks apart.

READ:  Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

“Though not life-threatening, raised SKs can make patients feel self-conscious, yet the majority of these lesions go untreated,” said Marina Peredo, M.D., F.A.A.D, an associate clinical professor of Dermatology at Mount Sinai Hospital in New York and founder of Skinfluence, a dermatology practice on the Upper East Side of Manhattan. “Now, with the introduction of ESKATA, my colleagues and I finally have a topical treatment option.”

Aclaris has partnered with McKesson, a global leader in healthcare supply chain management solutions, to support its sales force for the distribution of ESKATA.

ESKATA received Food and Drug Administration (FDA) approval on December 14, 2017 and will be offered to physicians as a self-pay treatment for patients. Prescribers may visit www.ESKATA.com for more information, to place an order for ESKATA and to view the full Prescribing Information.

READ:  Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease

It is important to see a healthcare provider with expertise in diagnosing skin conditions to confirm the diagnosis of raised SKs and determine whether ESKATA is an appropriate treatment.

Source: Aclaris Therapeutics, 101 Lindenwood Dr Ste 400, Malvern PA 19355

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee